Dr. Reddy's Laboratories Limited (RDY)
| Previous Close | 70.92 |
| Open | 73.40 |
| Bid | 73.98 x 800 |
| Ask | 74.10 x 1100 |
| Day's Range | 73.27 - 74.15 |
| 52 Week Range | 53.12 - 77.72 |
| Volume | |
| Avg. Volume | 191,262 |
| Market Cap | 12.416B |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | 19.68 |
| EPS (TTM) | 3.76 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.49 (0.69%) |
| Ex-Dividend Date | Jul 07, 2023 |
| 1y Target Est | 80.16 |
GlobeNewswirePharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
Business WireDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
ZacksWhy Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
